Sign in

Trial result ·

MesenSistem-EB: systemic haploidentical mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa associated with clinical benefits and correlated with MCP1 and sCD40L dynamics.

Written based on 1 research study on PubMed, searched on 15 Nov 2026.

What was studied

This early-stage trial tested donor stem cells in children with severe RDEB. RDEB is an inherited skin disease with ongoing inflammation. The cells came from the bone marrow of a haploidentical donor. Each child got 3 drips of cells into a vein, 21 days apart. There was no comparison group, and everyone knew what was given. The team checked safety, symptoms, blood signs of inflammation and immune cells for 12 months.

What they found

8 children finished the study. The cells were well tolerated, with no serious side effects. Over the long term, itch, sleep problems and tiredness were lower overall. In 7 of the 8 children, at least one key area got better. These areas were disease severity, itch, or inflammation. The median levels of CRP and fibrinogen stayed stable. Response was linked to changes in 2 blood proteins, MCP1 and sCD40L. The cells did not reliably stay in the body or lead to lasting C7 build-up.

What it means for patients

The authors say these cells seem safe in RDEB. They say the cells may help calm inflammation. The cells may hold back the expected rise in blood markers of inflammation. MCP1 and sCD40L might help show who will respond. Effects seemed partly shared and partly different from child to child. The authors see a possible role for the cells alongside other care.

Why it is not certain yet

Only 8 children finished the trial. It took place at a single center. There was no placebo or comparison group. Doctors and families knew which treatment was given. Immune cell changes did not clearly set apart the children who responded.

Source

MesenSistem-EB: systemic haploidentical mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa associated with clinical benefits and correlated with MCP1 and sCD40L dynamics.

PubMed · PMID 42164509

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Epidermolysis bullosa publications